Madrigal Secures Three New Resmetirom Patents, Extending IP Protection to 2045
MDGL sits 87% above its 52-week low of $286.44.
Summary
Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for resmetirom, the active ingredient in Rezdiffra, its approved MASH therapy. Two patents cover dosing refinements in F2/F3 patients—one for weight-based step-down with a moderate CYP2C8 inhibitor (protection to 2045) and another capping rosuvastatin at 20mg to reduce side effects (to 2042). A third patent covers a method of treating compensated cirrhosis (F4c), extending protection to 2042. This builds on the existing 2045 F2/F3 patent and strengthens the exclusivity runway for Rezdiffra, which generated $311M in Q1 2026 net sales. The expanded IP portfolio reduces near-term generic risk and supports the company's long-term commercial position in MASH. The F4c patent aligns with the ongoing Phase 3 outcomes trial, potentially broadening the label and market opportunity.
At the time of this announcement, MDGL was trading at $534.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.4B. The 52-week trading range was $286.44 to $615.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.